Compare ESEA & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESEA | BLSM |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.0M | 483.4M |
| IPO Year | 2005 | 2026 |
| Metric | ESEA | BLSM |
|---|---|---|
| Price | $64.25 | $13.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $91.75 | $35.40 |
| AVG Volume (30 Days) | 22.3K | ★ 131.5K |
| Earning Date | 11-17-2026 | 11-19-2026 |
| Dividend Yield | ★ 5.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.00 | $11.22 |
| 52 Week High | $79.67 | $27.99 |
| Indicator | ESEA | BLSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 42.76 |
| Support Level | $59.55 | $12.93 |
| Resistance Level | $73.19 | $17.53 |
| Average True Range (ATR) | 2.24 | 1.66 |
| MACD | -0.17 | -0.06 |
| Stochastic Oscillator | 10.46 | 44.62 |
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.